The use of neo-adjuvant therapy as standard care in people with locoregional and oligometastatic melanoma looks promising but it is not yet ready for prime time, concludes a ‘controversy’ debate that pitted neo-adjuvant against adjuvant or combination therapy. At the opening of the session ESMO 2019 delegates were asked if neoadjuvant therapy in patients with ...
Controversy debate: Neoadjuvant vs adjuvant therapy in advanced melanoma
By Nicola Garrett
30 Sep 2019